Further, TRAIL is specifically expressed in the brains of AD patients and completely absent in the brains of healthy controls [44], and anti-TRAIL antibodies reduce brain Aβ load and improve cognition in an AD mouse model [45]. This evidence concerns the gene TNFSF10 and Alzheimer disease.